Kobo Biotech reported a net loss of ₹52.30 crore and nil revenue for FY25. The company is under Corporate Insolvency Resolution Process (CIRP), with its resolution plan approved by NCLT on May 11, 2026.
Kobo Biotech Ltd. Reports ₹52.3 Cr Loss Amidst Insolvency
Net Loss: ₹52.30 crore (Year ended March 31, 2025)
Revenue from Operations: Nil (Year ended March 31, 2025)
Reader Takeaway: Approved resolution plan offers hope, but zero revenue and high liabilities remain key pressures.
What just happened
Kobo Biotech Limited has disclosed its financial results for the year ending March 31, 2025. During this period, the company recorded a net loss of ₹52.30 crore (₹5,229.8 lakh) and reported nil revenue from operations. The company is currently operating under the Corporate Insolvency Resolution Process (CIRP). Notably, the National Company Law Tribunal (NCLT), Hyderabad Bench, approved a resolution plan submitted by Beaufond Industries Limited on May 11, 2026.
Why this matters
This update is crucial for shareholders as it details the financial state of Kobo Biotech while it is under insolvency proceedings. The zero revenue and significant net loss underscore the company's distressed operational status. The NCLT's approval of a resolution plan is a significant step towards a potential revival, but its effective implementation will determine the company's future.
The backstory
Kobo Biotech has been grappling with significant financial and operational challenges, leading to its entry into the Corporate Insolvency Resolution Process (CIRP). The company's Solapur manufacturing plant has remained inactive due to regulatory and financial issues. The balance sheet as of March 31, 2025, shows total assets of ₹715.90 crore against liabilities of ₹2,097.30 crore, indicating a substantial deficit.
What changes now
The primary focus shifts to the implementation of the resolution plan approved by Beaufond Industries Limited. The powers of the Board of Directors remain suspended, with the Resolution Professional, Ms. Namrata Amol Randeri, continuing to manage the company's affairs during this transition period. The future operational and financial trajectory of Kobo Biotech hinges on the successful execution of this approved plan.
Risks to watch
Several concerns are highlighted, including significant statutory liabilities such as arrears in ESIC, Professional Tax, TDS, and Income Tax for various past assessment years. Compliance gaps, such as the lack of key managerial personnel (MD, CEO, CFO) and delayed BSE listing fee payments, also pose risks. The successful implementation of the resolution plan by Beaufond Industries is a critical watch point.
Peer comparison
Direct peer comparison is challenging given Kobo Biotech's current CIRP status. Companies undergoing insolvency typically operate with drastically different financial and operational parameters compared to their healthy counterparts. The focus for Kobo Biotech is on resolution rather than competitive market positioning.
Context metrics (time-bound)
- Net Loss: ₹52.30 crore for the year ended March 31, 2025.
- Revenue from Operations: Nil for the year ended March 31, 2025.
- Total Assets: ₹715.90 crore as at March 31, 2025.
- Total Liabilities: ₹2,097.30 crore as at March 31, 2025.
- EPS: (₹2.20) for the year ended March 31, 2025.
- Resolution Plan Approval: May 11, 2026.
What to track next
Investors should closely monitor the official communication from the Resolution Professional regarding the progress and milestones achieved in the implementation of Beaufond Industries Limited's resolution plan. Any updates on the operational status of the Solapur plant and compliance with statutory requirements will also be critical.